WEE1 and chronic myelogenous leukemia, BCR-ABL1 positive: Finally, our findings suggest that inhibiting Wee1 may increase CML cell chemosensitivity to IM while also delaying CML malignancy development in vivo, hinting that it might be a therapeutic target for future CML therapy.